Epoprostenol sodium structure
|
Common Name | Epoprostenol sodium | ||
---|---|---|---|---|
CAS Number | 61849-14-7 | Molecular Weight | 374.447 | |
Density | N/A | Boiling Point | 530.2ºC at 760mmHg | |
Molecular Formula | C20H31NaO5 | Melting Point | 168-170 °C | |
MSDS | Chinese USA | Flash Point | 182.1ºC | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Epoprostenol sodiumEpoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH)[1]. Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[2]. |
Name | prostacyclin sodium salt |
---|---|
Synonym | More Synonyms |
Description | Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH)[1]. Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[2]. |
---|---|
Related Catalog | |
References |
Boiling Point | 530.2ºC at 760mmHg |
---|---|
Melting Point | 168-170 °C |
Molecular Formula | C20H31NaO5 |
Molecular Weight | 374.447 |
Flash Point | 182.1ºC |
Exact Mass | 374.206909 |
PSA | 89.82000 |
LogP | 2.07380 |
Storage condition | −20°C |
Water Solubility | H2O: 1 mg/mL Hydrolyzes to 6-ketoprostaglandin F1α in aqueous solution. |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332 |
Precautionary Statements | P261-P280-P301 + P312 + P330 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R20/21/22 |
Safety Phrases | S22-S26-S36 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
Gingival pain: an unusual side effect of ziprasidone.
BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... |
|
PGI₂ signaling inhibits antigen uptake and increases migration of immature dendritic cells.
J. Leukoc. Biol. 94(1) , 77-88, (2013) PGI₂ signaling through IP inhibits allergen-induced inflammatory responses in mice. We reported previously that PGI₂ analogs decreased proinflammatory cytokine and chemokine production by mature BMDCs... |
|
Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins.
Mol. Immunol. 55(3-4) , 418-23, (2013) Evidence for the immunoregulatory function of lipid molecules in addition to proteins is accumulating. Based on our previous reports on the production of prostaglandin E₂ (PGE₂) and prostacyclin by hu... |
(5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-én-1-yl]hexahydro-2H-cyclopenta[b]fur-2-ylidène}pentanoate de sodium |
MFCD00135629 |
Natrium-(5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]hexahydro-2H-cyclopenta[b]fur-2-yliden}pentanoat |
PGI2 |
Flolan |
Prostacyclin sodium |
EINECS 234-237-8 |
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (9α,11α,13E,15S)- (1:1) |
PG12-NA |
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic Acid Sodium Salt |
U 53217A |
PGI2,SODIUM SALT |
Sodium PGI2 |
prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, monosodium salt, (5Z,9α,11α,13E,15S)- |
PGI2-NA |
PROSTAGLANDIN I2 |
Prostaglandin 12 |
PGI2 sodium |
sodium (5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]hexahydro-2H-cyclopenta[b]furan-2-ylidene}pentanoate |
Epoprostenol sodium |
Sodium (9α,11α,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oate |